Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Receives European Patent for Use of Ovarian Cancer Biomarkers

Premium

Fremont, Calif.-based proteomics diagnostics firm Vermillion announced this week that the European Patent Office has issued a decision to grant it a patent covering its use of biomarkers for the detection of ovarian cancer.

The patent, entitled "Use of Biomarkers for Detecting Ovarian Cancer," marks a significant step in the company's efforts to commercialize its OVA1 ovarian cancer protein biomarker test.

"The granting of this patent in Europe will help support our efforts to expand our commercialization into the EU," Vermillion CEO and executive chairperson Gail Page said in a statement. "We are actively engaged in the processes required to offer OVA1 in the EU."

The company, which emerged from Chapter 11 bankruptcy protection in January, received FDA approval for the OVA1 test in September 2009 and began selling the test in the US in March.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.